NYSE:ZBH - Zimmer Biomet Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $115.15 -0.96 (-0.83 %) (As of 05/22/2019 04:00 PM ET)Previous Close$116.11Today's Range$114.60 - $116.0952-Week Range$96.99 - $134.55Volume1.06 million shsAverage Volume1.27 million shsMarket Capitalization$23.58 billionP/E Ratio15.07Dividend Yield0.83%Beta1.19 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. Receive ZBH News and Ratings via Email Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNYSE:ZBH Previous SymbolNYSE:ZMH CUSIPN/A CIK1136869 Webhttp://www.zimmerbiomet.com/ Phone574-267-6131Debt Debt-to-Equity Ratio0.72 Current Ratio2.00 Quick Ratio0.97Price-To-Earnings Trailing P/E Ratio15.07 Forward P/E Ratio14.74 P/E Growth2.14 Sales & Book Value Annual Sales$7.93 billion Price / Sales2.97 Cash Flow$17.3943 per share Price / Cash Flow6.62 Book Value$56.35 per share Price / Book2.04Profitability EPS (Most Recent Fiscal Year)$7.64 Net Income$-379,200,000.00 Net Margins-3.90% Return on Equity13.24% Return on Assets6.28%Miscellaneous Employees19,000 Outstanding Shares204,798,000Market Cap$23.58 billion Next Earnings Date7/26/2019 (Estimated) OptionableOptionable Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions What is Zimmer Biomet's stock symbol? Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH." How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet? Zimmer Biomet announced a quarterly dividend on Thursday, March 7th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.24 per share on Tuesday, April 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date is Thursday, March 28th. View Zimmer Biomet's Dividend History. How were Zimmer Biomet's earnings last quarter? Zimmer Biomet Holdings Inc (NYSE:ZBH) issued its quarterly earnings data on Friday, April, 26th. The medical equipment provider reported $1.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.86 by $0.01. The medical equipment provider earned $1.98 billion during the quarter, compared to analyst estimates of $1.97 billion. Zimmer Biomet had a negative net margin of 3.90% and a positive return on equity of 13.24%. The business's revenue for the quarter was down 2.1% compared to the same quarter last year. During the same period last year, the firm earned $1.91 earnings per share. View Zimmer Biomet's Earnings History. When is Zimmer Biomet's next earnings date? Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Friday, July 26th 2019. View Earnings Estimates for Zimmer Biomet. What guidance has Zimmer Biomet issued on next quarter's earnings? Zimmer Biomet issued an update on its FY19 earnings guidance on Friday, April, 26th. The company provided earnings per share guidance of $7.70-7.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.80. The company issued revenue guidance of $7.89-7.97 billion, compared to the consensus revenue estimate of $7.95 billion. What price target have analysts set for ZBH? 23 analysts have issued twelve-month target prices for Zimmer Biomet's shares. Their predictions range from $96.00 to $155.00. On average, they expect Zimmer Biomet's share price to reach $130.1905 in the next year. This suggests a possible upside of 13.1% from the stock's current price. View Analyst Price Targets for Zimmer Biomet. What is the consensus analysts' recommendation for Zimmer Biomet? 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 3 sell ratings, 7 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zimmer Biomet. What are Wall Street analysts saying about Zimmer Biomet stock? Here are some recent quotes from research analysts about Zimmer Biomet stock: 1. According to Zacks Investment Research, "We believe escalating costs and expenses are denting the adjusted operating margin for Zimmer Biomet. Adverse currency movements continue to be a concern. Declining dental sales at CER also disappoint. On a positive note, the company witnessed strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business. Supported by focus on priority areas like quality remediation, supply recovery efforts and product launches, the company has again reported strong top-line numbers for its S.E.T segment. We are also upbeat about the company’s receipt of FDA 510(k) for the ROSA Knee System. Zimmer Biomet has outperformed its industry in the past six months." (4/13/2019) 2. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018) 3. Needham & Company LLC analysts commented, "In an 8-K filed this morning, ZBH disclosed that it received a FDA warning letter late Friday, 8/24.The warning letter isn’t a surprise in our view given ZBH’s previous two Form 483s. While we think that the risk of a consent decree has probably increased, we still think it is very unlikely given ZBH’s significant efforts and investments in addressing the Biomet plant issues. We don’t expect any impact to ZBH’s financial results from the warning letter and maintain our Buy rating." (8/27/2018) 4. Cantor Fitzgerald analysts commented, "We rate ZBH shares Overweight and have a 12-month price target of $150. ZBH has started a new era with recently hired the CEO of 10 years resigned in July. Under the new CEO near-term challenges persist, but we would expect the company to benefit from Hanson’s broader medtech background. ZBH is the least expensive large-cap medtech stock on a P/E basis, currently trading at a discount to the S&P. We believe the risk/reward is attractive at these levels and think there could be significant upside to shares if ZBH posts a couple of quarters of accelerating growth." (8/27/2018) Has Zimmer Biomet been receiving favorable news coverage? Headlines about ZBH stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zimmer Biomet earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the stock's share price in the near future. Who are some of Zimmer Biomet's key competitors? Some companies that are related to Zimmer Biomet include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Align Technology (ALGN), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Wound Management Technologies (WNDM), Establishment Labs (ESTA), RTI Surgical (RTIX) and ConforMIS (CFMS). What other stocks do shareholders of Zimmer Biomet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include Celgene (CELG), Cisco Systems (CSCO), General Electric (GE), UnitedHealth Group (UNH), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), AT&T (T), Teva Pharmaceutical Industries (TEVA), Visa (V) and Intel (INTC). Who are Zimmer Biomet's key executives? Zimmer Biomet's management team includes the folowing people: Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)Mr. Sang Yi, Pres of Asia Pacific (Age 57)Mr. Ivan Tornos, Group Pres of Orthopedics (Age 43) Who are Zimmer Biomet's major shareholders? Zimmer Biomet's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.04%), American Century Companies Inc. (2.27%), Wellington Management Group LLP (2.07%), Northern Trust Corp (1.76%), OppenheimerFunds Inc. (1.54%) and Nordea Investment Management AB (1.50%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Katarzyna Mazur-Hofsaess, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet. Which institutional investors are selling Zimmer Biomet stock? ZBH stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Nordea Investment Management AB, Morgan Stanley, FMR LLC, State of Tennessee Treasury Department, Strs Ohio, Jennison Associates LLC and Westpac Banking Corp. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet. Which institutional investors are buying Zimmer Biomet stock? ZBH stock was bought by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co, Boston Partners, Primecap Management Co. CA, Viking Global Investors LP, BlackRock Inc., OppenheimerFunds Inc., Goldman Sachs Group Inc. and Geode Capital Management LLC. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson and Syed A Jafry. View Insider Buying and Selling for Zimmer Biomet. How do I buy shares of Zimmer Biomet? Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zimmer Biomet's stock price today? One share of ZBH stock can currently be purchased for approximately $115.15. How big of a company is Zimmer Biomet? Zimmer Biomet has a market capitalization of $23.58 billion and generates $7.93 billion in revenue each year. The medical equipment provider earns $-379,200,000.00 in net income (profit) each year or $7.64 on an earnings per share basis. Zimmer Biomet employs 19,000 workers across the globe. What is Zimmer Biomet's official website? The official website for Zimmer Biomet is http://www.zimmerbiomet.com/. How can I contact Zimmer Biomet? Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected] MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 676 (Vote Outperform)Underperform Votes: 568 (Vote Underperform)Total Votes: 1,244MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Can systematic risk be avoided? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.